{"protocolSection":{"identificationModule":{"nctId":"NCT04623775","orgStudyIdInfo":{"id":"CA224-104"},"secondaryIdInfos":[{"id":"2020-004026-31","type":"EUDRACT_NUMBER"},{"id":"U1111-1256-8115","type":"REGISTRY","domain":"WHO"}],"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-02-17","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-01-11","type":"ACTUAL"},"completionDateStruct":{"date":"2026-02-27","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-11-05","studyFirstSubmitQcDate":"2020-11-05","studyFirstPostDateStruct":{"date":"2020-11-10","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-01-10","resultsFirstSubmitQcDate":"2025-02-27","resultsFirstPostDateStruct":{"date":"2025-03-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-10","lastUpdatePostDateStruct":{"date":"2025-10-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer"],"keywords":["Stage IV Non-small Cell Lunch Cancer","Recurrent Non-small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer","Relatlimab","Nivolumab","Chemotherapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":468,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab","Biological: Relatlimab","Drug: Carboplatin","Drug: Cisplatin","Drug: Paclitaxel","Drug: Nab-Paclitaxel","Drug: Pemetrexed"]},{"label":"Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab","Biological: Relatlimab","Drug: Carboplatin","Drug: Cisplatin","Drug: Paclitaxel","Drug: Nab-Paclitaxel","Drug: Pemetrexed"]},{"label":"Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab","Biological: Relatlimab","Drug: Carboplatin","Drug: Cisplatin","Drug: Paclitaxel","Drug: Pemetrexed"]},{"label":"Part 2: Arm D (Nivolumab + PDCT)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Nivolumab","Drug: Carboplatin","Drug: Cisplatin","Drug: Paclitaxel","Drug: Pemetrexed"]}],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","description":"Specified dose on specified days","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)","Part 2: Arm D (Nivolumab + PDCT)"]},{"type":"BIOLOGICAL","name":"Relatlimab","description":"Specified dose on specified days","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)"]},{"type":"DRUG","name":"Carboplatin","description":"Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)","Part 2: Arm D (Nivolumab + PDCT)"]},{"type":"DRUG","name":"Cisplatin","description":"Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)","Part 2: Arm D (Nivolumab + PDCT)"]},{"type":"DRUG","name":"Paclitaxel","description":"Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)","Part 2: Arm D (Nivolumab + PDCT)"]},{"type":"DRUG","name":"Nab-Paclitaxel","description":"Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))"]},{"type":"DRUG","name":"Pemetrexed","description":"Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.","armGroupLabels":["Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))","Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))","Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)","Part 2: Arm D (Nivolumab + PDCT)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1","description":"Percentage of participants with treatment related adverse events (TRAEs) leading to discontinuation within 12 weeks of first dose.\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"from first dose to 12 weeks after first dose"},{"measure":"ORR Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","timeFrame":"Approximately 14.8 Months"}],"secondaryOutcomes":[{"measure":"TRAEs Leading to Discontinuation in Part 1","description":"Number of participants with treatment related adverse events (TRAEs) leading to discontinuation based on grade.\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)"},{"measure":"Number of Participants With a Treatment Related AEs in Part 1","description":"Number of participants with a treatment related AE in part 1.\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)"},{"measure":"Number of Participants With Treatment Releted SAEs in Part 1","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \\[e.g., medical, surgical\\] to prevent one of the other serious outcomes listed in the definition).\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)"},{"measure":"Number of Participants With Treatment Releted Select AEs in Part 1","description":"AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nSelect Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)"},{"measure":"ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","timeFrame":"Approximately 14.8 Months"},{"measure":"DoR Per RECISTS v1.1 by BICR in Part 2","description":"Duration of Response (DOR) will be assessed by BICR. It is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR (per RECIST v1.1), or death due to any cause, whichever occurs first.","timeFrame":"Approximately up to 13.7 months"},{"measure":"Number of Participants With a AE in Part 2","description":"Number of participants with an adverse event (AE).\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)"},{"measure":"Number of Participants With a Treatment Related AEs in Part 2","description":"AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)"},{"measure":"Number of Participants With a Treatment Related SAEs in Part 2","description":"SAE is defined as a life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe). SAEs can also result in death. The AE requires inpatient hospitalization or causes prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \\[e.g., medical, surgical\\] to prevent one of the other serious outcomes listed in the definition above.)\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)"},{"measure":"Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2","description":"IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)"},{"measure":"ORR by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","timeFrame":"On Going"},{"measure":"ORR by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","timeFrame":"Ongoing"},{"measure":"PFS Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","timeFrame":"Ongoing"},{"measure":"PFS by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","timeFrame":"Ongoing"},{"measure":"PFS by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","timeFrame":"Ongoing"},{"measure":"PFS by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","timeFrame":"Ongoing"},{"measure":"Number of Participants With Treatment Releted Select AEs in Part 2","description":"AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nSelect Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.","timeFrame":"Ongoing"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Histologically confirmed metastatic non-small cell lung cancer (NSCLC) of squamous (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.\n* Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria.\n* No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease.\n\nExclusion Criteria\n\n* Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy.\n* Untreated CNS metastases.\n* Leptomeningeal metastases (carcinomatous meningitis).\n* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease).\n* Prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n* Other protocol-defined Inclusion/Exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0160","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Local Institution - 0081","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Local Institution - 0139","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Local Institution - 0153","city":"Jacksonville","state":"Florida","zip":"32204","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Local Institution - 0011","city":"Port Saint Lucie","state":"Florida","zip":"34952","country":"United States","geoPoint":{"lat":27.29393,"lon":-80.35033}},{"facility":"Local Institution - 0089","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Local Institution - 0121","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Local Institution - 0159","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Local Institution - 0002","city":"Louisville","state":"Kentucky","zip":"40241","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Local Institution - 0082","city":"Scarborough","state":"Maine","zip":"04074","country":"United States","geoPoint":{"lat":43.57814,"lon":-70.32172}},{"facility":"Local Institution - 0129","city":"Omaha","state":"Nebraska","zip":"68130","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Local Institution - 0152","city":"Howell Township","state":"New Jersey","zip":"07731","country":"United States","geoPoint":{"lat":40.1645,"lon":-74.20834}},{"facility":"Local Institution - 0124","city":"Johnson City","state":"New York","zip":"13790","country":"United States","geoPoint":{"lat":42.11563,"lon":-75.95881}},{"facility":"Local Institution - 0162","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Local Institution - 0128","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Local Institution - 0165","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Local Institution - 0097","city":"The Bronx","state":"New York","zip":"10461","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Local Institution - 0117","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Local Institution - 0156","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Local Institution - 0155","city":"Cleveland","state":"Ohio","zip":"44109","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Local Institution - 0084","city":"Lancaster","state":"Pennsylvania","zip":"17604","country":"United States","geoPoint":{"lat":40.03788,"lon":-76.30551}},{"facility":"Local Institution - 0147","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Local Institution - 0148","city":"Providence","state":"Rhode Island","zip":"02903","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Local Institution - 0083","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Local Institution - 0149","city":"Dallas","state":"Texas","zip":"75390-9179","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Local Institution - 0091","city":"Harlingen","state":"Texas","zip":"78550","country":"United States","geoPoint":{"lat":26.19063,"lon":-97.6961}},{"facility":"Local Institution - 0001","city":"Tyler","state":"Texas","zip":"75701","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Local Institution - 0092","city":"Spokane","state":"Washington","zip":"99208","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Local Institution - 0157","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"Local Institution - 0037","city":"Río Cuarto","state":"Córdoba Province","zip":"5800","country":"Argentina","geoPoint":{"lat":-33.13044,"lon":-64.35272}},{"facility":"Local Institution - 0021","city":"Buenos Aires","state":"Distrito Federal","zip":"C1426","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Local Institution - 0014","city":"Cuiudad Autonoma de Buenos Aires","state":"Distrito Federal","zip":"C1430EGF","country":"Argentina"},{"facility":"Local Institution - 0039","city":"Viedma","state":"Río Negro Province","zip":"8500","country":"Argentina","geoPoint":{"lat":-40.81519,"lon":-63.0004}},{"facility":"Local Institution - 0029","city":"Rosario","state":"Santa Fe Province","zip":"2000","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Local Institution - 0060","city":"Córdoba","zip":"5006","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Local Institution - 0038","city":"Córdoba","zip":"X5004FHP","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Local Institution - 0073","city":"La Rioja","zip":"F5300COE","country":"Argentina","geoPoint":{"lat":-29.41328,"lon":-66.85637}},{"facility":"Local Institution - 0055","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Local Institution - 0086","city":"Gosford","state":"New South Wales","zip":"2250","country":"Australia","geoPoint":{"lat":-33.4244,"lon":151.34399}},{"facility":"Local Institution - 0132","city":"Tamworth","state":"New South Wales","zip":"2340","country":"Australia","geoPoint":{"lat":-31.09048,"lon":150.92905}},{"facility":"Local Institution - 0057","city":"Adelaide","state":"South Australia","zip":"5087","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Local Institution - 0130","city":"Ballarat","state":"Victoria","zip":"3350","country":"Australia","geoPoint":{"lat":-37.56622,"lon":143.84957}},{"facility":"Local Institution - 0138","city":"Bendigo","state":"Victoria","zip":"3550","country":"Australia","geoPoint":{"lat":-36.75818,"lon":144.28024}},{"facility":"Local Institution - 0141","city":"Box Hill","state":"Victoria","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"Local Institution - 0109","city":"Frankston","state":"Victoria","zip":"3199","country":"Australia","geoPoint":{"lat":-38.14458,"lon":145.12291}},{"facility":"Local Institution - 0119","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","geoPoint":{"lat":-32.06987,"lon":115.83757}},{"facility":"Local Institution - 0085","city":"Nedlands","state":"Western Australia","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"Local Institution - 0090","city":"Graz","zip":"8036","country":"Austria","geoPoint":{"lat":47.06733,"lon":15.44197}},{"facility":"Local Institution - 0126","city":"Vienna","zip":"1090","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Local Institution - 0127","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Local Institution - 0131","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Local Institution - 0125","city":"Roeselare","zip":"8800","country":"Belgium","geoPoint":{"lat":50.94653,"lon":3.12269}},{"facility":"Local Institution - 0063","city":"Natal","state":"Rio Grande do Norte","zip":"59062 000","country":"Brazil","geoPoint":{"lat":-5.795,"lon":-35.20944}},{"facility":"Local Institution - 0161","city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Local Institution - 0116","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90050-170","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Local Institution - 0112","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Local Institution - 0107","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Local Institution - 0111","city":"Santo André","state":"São Paulo","zip":"09060-870","country":"Brazil","geoPoint":{"lat":-23.66389,"lon":-46.53833}},{"facility":"Local Institution - 0072","city":"Rio de Janeiro","zip":"20220-410","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Local Institution - 0163","city":"São Paulo","zip":"04014-002","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Local Institution - 0120","city":"São Paulo","zip":"08270-120","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Local Institution - 0079","city":"Santiago","state":"Santiago Metropolitan","zip":"0","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0041","city":"Santiago","state":"Santiago Metropolitan","zip":"7500713","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0016","city":"Santiago","state":"Santiago Metropolitan","zip":"7500921","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Local Institution - 0008","city":"Rennes","state":"Ille-Et-Vilaine","zip":"35000","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Local Institution - 0007","city":"Dijon","zip":"21 000","country":"France","geoPoint":{"lat":47.31344,"lon":5.01391}},{"facility":"Local Institution - 0144","city":"Le Mans","zip":"72037","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"Local Institution - 0102","city":"Paris","zip":"75014","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0035","city":"Paris","zip":"75018","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0006","city":"Saint-Mandé","zip":"94160","country":"France","geoPoint":{"lat":48.83864,"lon":2.41579}},{"facility":"Local Institution - 0110","city":"Paris","state":"Île-de-France Region","zip":"75005","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0065","city":"Essen","state":"North Rhine-Westphalia","zip":"45136","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Local Institution - 0103","city":"Berlin","zip":"12351","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Local Institution - 0045","city":"Berlin","zip":"13585","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Local Institution - 0062","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Local Institution - 0058","city":"Homburg","zip":"66421","country":"Germany","geoPoint":{"lat":49.32637,"lon":7.33867}},{"facility":"Local Institution - 0108","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"Local Institution - 0071","city":"Marburg","zip":"35043","country":"Germany","geoPoint":{"lat":50.80904,"lon":8.77069}},{"facility":"Local Institution - 0050","city":"Paderborn","zip":"33098","country":"Germany","geoPoint":{"lat":51.71905,"lon":8.75439}},{"facility":"Local Institution - 0030","city":"Ravensburg","zip":"88212","country":"Germany","geoPoint":{"lat":47.78198,"lon":9.61062}},{"facility":"Local Institution - 0133","city":"Elm Park","state":"Dublin","zip":"4","country":"Ireland"},{"facility":"Local Institution - 0023","city":"Dublin","zip":"00009","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Local Institution - 0106","city":"Rome","state":"RA","zip":"00144","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Local Institution - 0028","city":"Candiolo","zip":"10060","country":"Italy","geoPoint":{"lat":44.95858,"lon":7.59812}},{"facility":"Local Institution - 0009","city":"Catania","zip":"95125","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Local Institution - 0032","city":"Genova","zip":"16149","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Local Institution - 0059","city":"Milan","zip":"20141","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Local Institution - 0164","city":"Pesaro","zip":"61122","country":"Italy","geoPoint":{"lat":43.90921,"lon":12.9164}},{"facility":"Local Institution - 0019","city":"Siena","zip":"53100","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Local Institution - 0070","city":"Mexico City","state":"Mexico City","zip":"14050","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Local Institution - 0115","city":"Monterrey","state":"Nuevo León","zip":"64710","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Local Institution - 0013","city":"San Pedro Garza García","state":"Nuevo León","zip":"66220","country":"Mexico","geoPoint":{"lat":25.6604,"lon":-100.40651}},{"facility":"Local Institution - 0020","city":"Toluca","state":"State of Mexico","zip":"50090","country":"Mexico","geoPoint":{"lat":19.28786,"lon":-99.65324}},{"facility":"Local Institution - 0053","city":"Harderwijk","state":"Gelderland","zip":"3844","country":"Netherlands","geoPoint":{"lat":52.34167,"lon":5.62083}},{"facility":"Local Institution - 0158","city":"Arnhem","zip":"6815","country":"Netherlands","geoPoint":{"lat":51.98,"lon":5.91111}},{"facility":"Local Institution - 0145","city":"Gdynia","zip":"81-519","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Local Institution - 0036","city":"Lublin","zip":"20-090","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Local Institution - 0031","city":"Lublin","zip":"20-093","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Local Institution - 0080","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Local Institution - 0088","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Local Institution - 0099","city":"Cluj-Napoca","state":"Cluj","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Local Institution - 0017","city":"Craiova","state":"Dolj","zip":"200385","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Local Institution - 0012","city":"Craiova","state":"Jud. Dolj","zip":"200094","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Local Institution - 0069","city":"Timișoara","state":"Timiș County","zip":"300166","country":"Romania","geoPoint":{"lat":45.75372,"lon":21.22571}},{"facility":"Local Institution - 0052","city":"Craiova","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Arkhangelsk Clinical Oncological Dispensary","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"LLC Eurocityclinic","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"FSBI &quot,Research Institute of Influenza named after A.A. Smorodintsev &quot,of the MoH of the Rus","city":"Saint Petersburg","zip":"197376","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Local Institution - 0075","city":"Seville","state":"Andalusia","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Local Institution - 0137","city":"Badalona","state":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Local Institution - 0024","city":"Barcelona","state":"Catalonia","zip":"08008","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0051","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Local Institution - 0154","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0048","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0061","city":"Las Palmas","zip":"35016","country":"Spain","geoPoint":{"lat":28.58232,"lon":-16.16555}},{"facility":"Local Institution - 0074","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0123","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0042","city":"Málaga","zip":"29011","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Local Institution - 0043","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Local Institution - 0015","city":"Basel","zip":"4031","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Local Institution - 0104","city":"Sankt Gallen","zip":"9007","country":"Switzerland","geoPoint":{"lat":47.42391,"lon":9.37477}},{"facility":"Local Institution - 0135","city":"Middlesbrough","state":"Cleveland","zip":"TS4 3BW","country":"United Kingdom","geoPoint":{"lat":54.57623,"lon":-1.23483}},{"facility":"Local Institution - 0101","city":"London","state":"Greater London","zip":"NW1 2PG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Local Institution - 0095","city":"Manchester","state":"Lancashire","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Local Institution - 0067","city":"Leicester","zip":"LE15WW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT04623775.html"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"468 Randomized and 463 Treated","groups":[{"id":"FG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"FG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"FG002","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"FG003","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"periods":[{"title":"Randomization","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"80"},{"groupId":"FG002","numSubjects":"158"},{"groupId":"FG003","numSubjects":"151"}]},{"type":"COMPLETED","comment":"Completed = Will Receive Treatment","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"79"},{"groupId":"FG002","numSubjects":"158"},{"groupId":"FG003","numSubjects":"149"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]}],"dropWithdraws":[{"type":"No Longer Meets Study Criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrew Consent","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Other Reasons","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]},{"title":"Treatment Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"79"},{"groupId":"FG002","numSubjects":"158"},{"groupId":"FG003","numSubjects":"149"}]},{"type":"COMPLETED","comment":"= on going treatment","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"61"},{"groupId":"FG003","numSubjects":"60"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"97"},{"groupId":"FG003","numSubjects":"89"}]}],"dropWithdraws":[{"type":"participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"poor/non compliance","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"participant no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"administrative reasons by sponsor","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"other reasons","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"disease progression","reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"35"},{"groupId":"FG002","numSubjects":"63"},{"groupId":"FG003","numSubjects":"63"}]},{"type":"study drug toxicity","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"12"}]},{"type":"AE unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"9"}]},{"type":"participant request to discontinue treatment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"BG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"BG002","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"BG003","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"158"},{"groupId":"BG003","value":"151"},{"groupId":"BG004","value":"468"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"72"},{"groupId":"BG004","value":"224"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"85"},{"groupId":"BG003","value":"79"},{"groupId":"BG004","value":"244"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"172"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"103"},{"groupId":"BG003","value":"94"},{"groupId":"BG004","value":"296"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"87"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"91"},{"groupId":"BG003","value":"88"},{"groupId":"BG004","value":"260"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"35"},{"groupId":"BG004","value":"121"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"148"},{"groupId":"BG003","value":"141"},{"groupId":"BG004","value":"441"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"21"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1","description":"Percentage of participants with treatment related adverse events (TRAEs) leading to discontinuation within 12 weeks of first dose.\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All Treated Dose-Safety Evaluable participants in part 1","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"from first dose to 12 weeks after first dose","groups":[{"id":"OG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"1.6","upperLimit":"13.8"},{"groupId":"OG001","value":"12.1","lowerLimit":"5.4","upperLimit":"22.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"-6.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.0","ciUpperLimit":"3.0"}]},{"type":"PRIMARY","title":"ORR Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","populationDescription":"All randomized participants in Part 2","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Approximately 14.8 Months","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","lowerLimit":"43.8","upperLimit":"57.4"},{"groupId":"OG001","value":"43.0","lowerLimit":"36.2","upperLimit":"50.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"1.39","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.94","ciUpperLimit":"2.05"}]},{"type":"SECONDARY","title":"TRAEs Leading to Discontinuation in Part 1","description":"Number of participants with treatment related adverse events (TRAEs) leading to discontinuation based on grade.\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0","populationDescription":"All treated participants in Part 1","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)","groups":[{"id":"OG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"}]}],"classes":[{"title":"Any Grade","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"}]}]},{"title":"Grade 3 to 4","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Treatment Related AEs in Part 1","description":"Number of participants with a treatment related AE in part 1.\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0","populationDescription":"All treated participants in Part 1","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)","groups":[{"id":"OG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Releted SAEs in Part 1","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \\[e.g., medical, surgical\\] to prevent one of the other serious outcomes listed in the definition).\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All treated participants in Part 1","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)","groups":[{"id":"OG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"}]}],"classes":[{"title":"Any Grade","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"24"}]}]},{"title":"Grade 3 to 4","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Releted Select AEs in Part 1","description":"AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nSelect Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All treated participants in Part 1","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)","groups":[{"id":"OG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"}]}],"classes":[{"title":"Gastrointestinal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"15"}]}]},{"title":"Hepatic","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"}]}]},{"title":"Pulmonary","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"Renal","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}]},{"title":"Skin","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"18"}]}]},{"title":"Hypersensitivity/Infusion Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","populationDescription":"All randomized participants in Part 2","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Approximately 14.8 Months","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"PD-L1 <1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","lowerLimit":"38.2","upperLimit":"59.0"},{"groupId":"OG001","value":"44.8","lowerLimit":"34.4","upperLimit":"55.5"}]}]},{"title":"PD-L1 >= 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.2","lowerLimit":"43.3","upperLimit":"62.8"},{"groupId":"OG001","value":"39.4","lowerLimit":"29.7","upperLimit":"49.9"}]}]},{"title":"Not Quantifiable","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","lowerLimit":"16.9","upperLimit":"74.9"},{"groupId":"OG001","value":"53.8","lowerLimit":"28.7","upperLimit":"77.6"}]}]}]},{"type":"SECONDARY","title":"DoR Per RECISTS v1.1 by BICR in Part 2","description":"Duration of Response (DOR) will be assessed by BICR. It is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR (per RECIST v1.1), or death due to any cause, whichever occurs first.","populationDescription":"All randomized participants in Part 2","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Approximately up to 13.7 months","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.41","lowerLimit":"7.43","upperLimit":"NA","comment":"Upper limit was not reached due to an insufficient number of participants with events"},{"groupId":"OG001","value":"7.10","lowerLimit":"5.62","upperLimit":"NA","comment":"Upper limit was not reached due to an insufficient number of participants with events"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a AE in Part 2","description":"Number of participants with an adverse event (AE).\n\nAE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All treated participants in Part 2","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Any Grade","categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"147"}]}]},{"title":"Grade 3 to 4","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"85"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"19"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Treatment Related AEs in Part 2","description":"AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All treated participants in Part 2","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Any Grade","categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"138"}]}]},{"title":"Grade 3 to 4","categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"78"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Treatment Related SAEs in Part 2","description":"SAE is defined as a life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe). SAEs can also result in death. The AE requires inpatient hospitalization or causes prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \\[e.g., medical, surgical\\] to prevent one of the other serious outcomes listed in the definition above.)\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All treated participants in Part 2","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Any Grade","categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"36"}]}]},{"title":"Grade 3 to 4","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"28"}]}]},{"title":"Grade 5","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2","description":"IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.\n\nGrading will be determined for severity according to the NCI CTCAE v5.0.","populationDescription":"All treated participants in Part 2","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)","groups":[{"id":"OG000","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT"},{"id":"OG001","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Adrenal Insufficiency","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Hypothyroidism/Thyroiditis","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"13"}]}]},{"title":"Hypothyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"13"}]}]},{"title":"Thyroiditis","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Diabetes Mellitus","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyperthyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}]},{"title":"Hypophysitis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"ORR by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"On Going","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"ORR by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"Ongoing","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"PFS Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"Ongoing","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"PFS by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"Ongoing","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"PFS by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"Ongoing","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"PFS by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2","description":"Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"Ongoing","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants With Treatment Releted Select AEs in Part 2","description":"AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.\n\nSelect Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2027-01","timeFrame":"Ongoing","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All-Cause mortality, Adverse Events and Serious Adverse Events: (From first dose to last dose + 135 days): Approximately 36 Months","description":"The number at Risk for All-Cause Mortality represents all Treated Participants. The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication","eventGroups":[{"id":"EG000","title":"Part 1: Treatment A","description":"Nivo 360mg Q3W + Rela 720mg Q3W + Histology Based PDCT","deathsNumAffected":47,"deathsNumAtRisk":77,"seriousNumAffected":46,"seriousNumAtRisk":77,"otherNumAffected":74,"otherNumAtRisk":77},{"id":"EG001","title":"Part 1: Treatment B","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT","deathsNumAffected":46,"deathsNumAtRisk":79,"seriousNumAffected":52,"seriousNumAtRisk":79,"otherNumAffected":78,"otherNumAtRisk":79},{"id":"EG002","title":"Part 2: Treatment C","description":"Nivo 360mg Q3W + Rela 360mg Q3W + Histology Based PDCT","deathsNumAffected":79,"deathsNumAtRisk":158,"seriousNumAffected":103,"seriousNumAtRisk":158,"otherNumAffected":151,"otherNumAtRisk":158},{"id":"EG003","title":"Part 2: Treatment D","description":"Nivo 360mg Q3W + Histology Based PDCT","deathsNumAffected":70,"deathsNumAtRisk":149,"seriousNumAffected":81,"seriousNumAtRisk":149,"otherNumAffected":145,"otherNumAtRisk":149}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":6,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":7,"numAtRisk":149}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":10,"numAtRisk":149}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Glucocorticoid deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Colonic fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Gastrointestinal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Intestinal pseudo-obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Terminal ileitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cholangitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Suspected drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Haemophagocytic lymphohistiocytosis","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Infusion related hypersensitivity reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cholangitis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":14,"numAtRisk":158},{"groupId":"EG003","numAffected":10,"numAtRisk":149}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pneumonia respiratory syncytial viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Urinary tract infection staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Adenovirus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Troponin I increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Troponin T increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Osteonecrosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Lymphangiosis carcinomatosa","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":40,"numAtRisk":158},{"groupId":"EG003","numAffected":36,"numAtRisk":149}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Cerebral cyst","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Immune-mediated encephalitis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Substance-induced psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Glomerulonephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Malignant pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Aortic stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Peripheral embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Raynaud's phenomenon","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":77},{"groupId":"EG001","numAffected":43,"numAtRisk":79},{"groupId":"EG002","numAffected":109,"numAtRisk":158},{"groupId":"EG003","numAffected":92,"numAtRisk":149}]},{"term":"Eosinophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":16,"numAtRisk":158},{"groupId":"EG003","numAffected":12,"numAtRisk":149}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":77},{"groupId":"EG001","numAffected":12,"numAtRisk":79},{"groupId":"EG002","numAffected":17,"numAtRisk":158},{"groupId":"EG003","numAffected":16,"numAtRisk":149}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":20,"numAtRisk":158},{"groupId":"EG003","numAffected":9,"numAtRisk":149}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":77},{"groupId":"EG001","numAffected":29,"numAtRisk":79},{"groupId":"EG002","numAffected":38,"numAtRisk":158},{"groupId":"EG003","numAffected":38,"numAtRisk":149}]},{"term":"Neutrophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":10,"numAtRisk":158},{"groupId":"EG003","numAffected":10,"numAtRisk":149}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":77},{"groupId":"EG001","numAffected":16,"numAtRisk":79},{"groupId":"EG002","numAffected":47,"numAtRisk":158},{"groupId":"EG003","numAffected":34,"numAtRisk":149}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":9,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":77},{"groupId":"EG001","numAffected":12,"numAtRisk":79},{"groupId":"EG002","numAffected":15,"numAtRisk":158},{"groupId":"EG003","numAffected":6,"numAtRisk":149}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":77},{"groupId":"EG001","numAffected":10,"numAtRisk":79},{"groupId":"EG002","numAffected":26,"numAtRisk":158},{"groupId":"EG003","numAffected":14,"numAtRisk":149}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":6,"numAtRisk":149}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":9,"numAtRisk":158},{"groupId":"EG003","numAffected":8,"numAtRisk":149}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":77},{"groupId":"EG001","numAffected":17,"numAtRisk":79},{"groupId":"EG002","numAffected":33,"numAtRisk":158},{"groupId":"EG003","numAffected":20,"numAtRisk":149}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":77},{"groupId":"EG001","numAffected":18,"numAtRisk":79},{"groupId":"EG002","numAffected":34,"numAtRisk":158},{"groupId":"EG003","numAffected":30,"numAtRisk":149}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":77},{"groupId":"EG001","numAffected":29,"numAtRisk":79},{"groupId":"EG002","numAffected":55,"numAtRisk":158},{"groupId":"EG003","numAffected":40,"numAtRisk":149}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":77},{"groupId":"EG001","numAffected":16,"numAtRisk":79},{"groupId":"EG002","numAffected":27,"numAtRisk":158},{"groupId":"EG003","numAffected":20,"numAtRisk":149}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":77},{"groupId":"EG001","numAffected":27,"numAtRisk":79},{"groupId":"EG002","numAffected":37,"numAtRisk":158},{"groupId":"EG003","numAffected":36,"numAtRisk":149}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":7,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":77},{"groupId":"EG001","numAffected":25,"numAtRisk":79},{"groupId":"EG002","numAffected":43,"numAtRisk":158},{"groupId":"EG003","numAffected":37,"numAtRisk":149}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":9,"numAtRisk":158},{"groupId":"EG003","numAffected":10,"numAtRisk":149}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":1,"numAtRisk":79},{"groupId":"EG002","numAffected":5,"numAtRisk":158},{"groupId":"EG003","numAffected":8,"numAtRisk":149}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":17,"numAtRisk":158},{"groupId":"EG003","numAffected":18,"numAtRisk":149}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":11,"numAtRisk":79},{"groupId":"EG002","numAffected":18,"numAtRisk":158},{"groupId":"EG003","numAffected":11,"numAtRisk":149}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":11,"numAtRisk":158},{"groupId":"EG003","numAffected":14,"numAtRisk":149}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":77},{"groupId":"EG001","numAffected":15,"numAtRisk":79},{"groupId":"EG002","numAffected":13,"numAtRisk":158},{"groupId":"EG003","numAffected":17,"numAtRisk":149}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":77},{"groupId":"EG001","numAffected":15,"numAtRisk":79},{"groupId":"EG002","numAffected":14,"numAtRisk":158},{"groupId":"EG003","numAffected":17,"numAtRisk":149}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":10,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Blood calcium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":7,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":7,"numAtRisk":158},{"groupId":"EG003","numAffected":8,"numAtRisk":149}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":18,"numAtRisk":158},{"groupId":"EG003","numAffected":16,"numAtRisk":149}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Blood magnesium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":6,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":9,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":11,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":0,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":5,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":77},{"groupId":"EG001","numAffected":10,"numAtRisk":79},{"groupId":"EG002","numAffected":19,"numAtRisk":158},{"groupId":"EG003","numAffected":12,"numAtRisk":149}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":77},{"groupId":"EG001","numAffected":13,"numAtRisk":79},{"groupId":"EG002","numAffected":22,"numAtRisk":158},{"groupId":"EG003","numAffected":17,"numAtRisk":149}]},{"term":"Troponin T increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":6,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":15,"numAtRisk":158},{"groupId":"EG003","numAffected":21,"numAtRisk":149}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":12,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":77},{"groupId":"EG001","numAffected":24,"numAtRisk":79},{"groupId":"EG002","numAffected":27,"numAtRisk":158},{"groupId":"EG003","numAffected":34,"numAtRisk":149}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":19,"numAtRisk":158},{"groupId":"EG003","numAffected":8,"numAtRisk":149}]},{"term":"Hyperphosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":77},{"groupId":"EG001","numAffected":0,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":6,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":9,"numAtRisk":149}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":7,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":11,"numAtRisk":149}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":16,"numAtRisk":158},{"groupId":"EG003","numAffected":17,"numAtRisk":149}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":11,"numAtRisk":79},{"groupId":"EG002","numAffected":12,"numAtRisk":158},{"groupId":"EG003","numAffected":16,"numAtRisk":149}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":77},{"groupId":"EG001","numAffected":11,"numAtRisk":79},{"groupId":"EG002","numAffected":26,"numAtRisk":158},{"groupId":"EG003","numAffected":22,"numAtRisk":149}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":12,"numAtRisk":158},{"groupId":"EG003","numAffected":6,"numAtRisk":149}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":15,"numAtRisk":158},{"groupId":"EG003","numAffected":10,"numAtRisk":149}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":1,"numAtRisk":158},{"groupId":"EG003","numAffected":1,"numAtRisk":149}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":9,"numAtRisk":158},{"groupId":"EG003","numAffected":7,"numAtRisk":149}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":13,"numAtRisk":158},{"groupId":"EG003","numAffected":11,"numAtRisk":149}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":6,"numAtRisk":158},{"groupId":"EG003","numAffected":7,"numAtRisk":149}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":77},{"groupId":"EG001","numAffected":11,"numAtRisk":79},{"groupId":"EG002","numAffected":12,"numAtRisk":158},{"groupId":"EG003","numAffected":13,"numAtRisk":149}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":15,"numAtRisk":158},{"groupId":"EG003","numAffected":7,"numAtRisk":149}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":6,"numAtRisk":158},{"groupId":"EG003","numAffected":9,"numAtRisk":149}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":6,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":7,"numAtRisk":149}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":77},{"groupId":"EG001","numAffected":11,"numAtRisk":79},{"groupId":"EG002","numAffected":19,"numAtRisk":158},{"groupId":"EG003","numAffected":16,"numAtRisk":149}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":77},{"groupId":"EG001","numAffected":18,"numAtRisk":79},{"groupId":"EG002","numAffected":15,"numAtRisk":158},{"groupId":"EG003","numAffected":14,"numAtRisk":149}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":0,"numAtRisk":149}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":3,"numAtRisk":79},{"groupId":"EG002","numAffected":7,"numAtRisk":158},{"groupId":"EG003","numAffected":5,"numAtRisk":149}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":77},{"groupId":"EG001","numAffected":5,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":6,"numAtRisk":149}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":2,"numAtRisk":79},{"groupId":"EG002","numAffected":3,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":77},{"groupId":"EG001","numAffected":8,"numAtRisk":79},{"groupId":"EG002","numAffected":12,"numAtRisk":158},{"groupId":"EG003","numAffected":19,"numAtRisk":149}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":77},{"groupId":"EG001","numAffected":4,"numAtRisk":79},{"groupId":"EG002","numAffected":4,"numAtRisk":158},{"groupId":"EG003","numAffected":3,"numAtRisk":149}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":8,"numAtRisk":158},{"groupId":"EG003","numAffected":16,"numAtRisk":149}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":23,"numAtRisk":158},{"groupId":"EG003","numAffected":16,"numAtRisk":149}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":2,"numAtRisk":158},{"groupId":"EG003","numAffected":2,"numAtRisk":149}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":7,"numAtRisk":158},{"groupId":"EG003","numAffected":8,"numAtRisk":149}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":77},{"groupId":"EG001","numAffected":7,"numAtRisk":79},{"groupId":"EG002","numAffected":9,"numAtRisk":158},{"groupId":"EG003","numAffected":4,"numAtRisk":149}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"1-855-907-3286"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2024-09-11","uploadDate":"2025-02-27T10:07","filename":"Prot_SAP_001.pdf","size":29029419}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Canada","New Zealand","Turkey (Türkiye)"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-02-05","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"},{"id":"C000721227","term":"relatlimab"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}